The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk

References

• De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23–34.
   PubMed Web of Science ®Google Scholar
• Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199.
   PubMed Web of Science ®Google Scholar
• Cox JD. Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys. 2012;82:1042–1044.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C. Dose escalation in lung cancer: have we gone full circle? Lancet Oncol. 2015;16:125–127.
   PubMed Web of Science ®Google Scholar
• Chen C, Uyterlinde W, Sonke JJ, et al. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother Oncol. 2013;108:337–341.
   PubMed Web of Science ®Google Scholar
• Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35:1387–1394.
   PubMed Web of Science ®Google Scholar
• Cannon DM, Mehta MP, Adkison JB, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013;31:4343–4348.
   PubMed Web of Science ®Google Scholar
• Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys. 2005;61:64–69.
   PubMed Web of Science ®Google Scholar
• Evans JD, Gomez DR, Amini A, et al. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol. 2013;106:327–332.
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.
   PubMed Web of Science ®Google Scholar
• Møller DS, Khalil AA, Knap MM, et al. Adaptive radiotherapy of lung cancer patients with pleural effusion or atelectasis. Radiother Oncol. 2014;110:517–522.
   PubMed Web of Science ®Google Scholar
• Kwint M, Conijn S, Schaake E, et al. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. Radiother Oncol. 2014;113:392–397.
   PubMed Web of Science ®Google Scholar
• Møller DS, Holt MI, Alber M, et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. Radiother Oncol. 2016;121:32–38.
   PubMed Web of Science ®Google Scholar
• Møller DS, Nielsen TB, Brink C, et al. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-centre phase-III study. Radiother Oncol. Forthcoming. [cited 2017 Jul 5]. DOI:10.1016/j.radonc.2017.06.022
   Web of Science ®Google Scholar
• Wolthaus JW, Schneider C, Sonke JJ, et al. Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 2006;65:1560–1571.
   PubMed Web of Science ®Google Scholar
• Underberg RW, Lagerwaard FJ, Slotman BJ, et al. Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:253–260.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys. 2011;81:1442–1457.
   PubMed Web of Science ®Google Scholar
• Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–18.
   PubMed Web of Science ®Google Scholar
• Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041–1047.
   PubMed Web of Science ®Google Scholar
• Rønde H, Hoffmann L. Validation of Varian’s AAA algorithm with focus on lung treatments. Acta Oncol. 2009;48:209–215.
   PubMed Web of Science ®Google Scholar
• Hoffmann L, Holt MI, Knap MM, et al. Anatomical landmarks accurately determine interfractional lymph node shifts during radiotherapy of lung cancer patients. Radiother Oncol. 2015;116:64–69.
   PubMed Web of Science ®Google Scholar
• Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017;123:276–281.
   PubMed Web of Science ®Google Scholar
• Knap MM, Hoffmann L, Nordsmark M, et al. Daily cone-beam computed tomography used to determine tumour shrinkage and localisation in lung cancer patients. Acta Oncol. 2010;49:1077–1084.
   PubMed Web of Science ®Google Scholar
• Schaake EE, Rossi MMG, Buikhuisen WA, et al. Differential motion between mediastinal lymph nodes and primary tumor in radically irradiated lung cancer patients. Int J Radiat Oncol Biol Phys. 2014;90:959–966.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, De Ruysscher D, van der Salm A, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104:67–71.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26:2457–2463.
   PubMed Web of Science ®Google Scholar
• Kimsey F, McKay J, Gefter J, et al. Dose-response model for chest wall tolerance of stereotactic body radiation therapy. Semin Radiat Oncol. 2016;26:129–134.
   PubMed Web of Science ®Google Scholar
• Uyterlinde W, Chen C, Belderbos J, et al. Fractures of thoracic vertebrae in patients with locally advanced non-small cell lung carcinoma treated with intensity modulated radiotherapy. Radiother Oncol. 2016;118:437–441.
   PubMed Web of Science ®Google Scholar
• Sibolt P, Ottosson W, Sjöström D, et al. Adaptation requirements due to anatomical changes in free-breathing and deep-inspiration breath-hold for standard and dose-escalated radiotherapy of lung cancer patients. Acta Oncol. 2015;54:1453–1460.
   PubMed Web of Science ®Google Scholar